EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
about
Precision medicine in breast cancer: reality or utopia?Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system.Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early Stage Lung Cancers.GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer.Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems TheoryRoles of Integrin α6β4 Glycosylation in Cancer.Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis.Long Non-Coding RNA (LncRNA) HOXA11-AS Promotes Breast Cancer Invasion and Metastasis by Regulating Epithelial-Mesenchymal Transition.Integrins and Exosomes, a Dangerous Liaison in Cancer Progression.Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung CancerComplex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.Deregulated expression of microRNA-200b/c and SUZ12, a Polycomb repressive complex 2 subunit, in chemoresistant colorectal cancer cells.Glycans as Regulatory Elements of the Insulin/IGF System: Impact in Cancer Progression.The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis.Management and potentialities of primary cancer cultures in preclinical and translational studies.Commentary: HNRNPLL, a newly identified colorectal cancer metastasis suppressor, modulates alternative splicing of CD44 during epithelial-mesenchymal transition.miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis.DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.Circular RNA profile indicates circular RNA VRK1 is negatively related with breast cancer stem cells.Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop.Klf4 reduces stemness phenotype, triggers mesenchymal-epithelial transition (MET)-like molecular changes, and prevents tumor progression in nasopharygeal carcinoma.Targeting Metastasis with Snake Toxins: Molecular Mechanisms.Drug Resistance Driven by Cancer Stem Cells and Their Niche.Epithelial Mesenchymal Transition in Embryonic Development, Tissue Repair and Cancer: A Comprehensive Overview.Biomaterials-Based Approaches to Tumor Spheroid and Organoid Modeling.High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric.Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.Mesenchymal stromal cell engagement in cancer cell epithelial to mesenchymal transition.TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma.Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma.PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling.Histone Variant MacroH2A1 Plays an Isoform-Specific Role in Suppressing Epithelial-Mesenchymal Transition.Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.Mitochondrial Dysfunction: A Novel Potential Driver of Epithelial-to-Mesenchymal Transition in Cancer.In vivo optical imaging of cancer cell function and tumor microenvironment.Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.
P2860
Q33809114-994234A6-563B-4ECF-B8B5-E0D6F10FD9DEQ33869764-AB0A8A3D-B53D-47FC-844C-E3918C59E38FQ38431117-998B5A37-6BBF-4947-A591-3F5D423F9B7DQ38630252-A5EACA44-BA36-4140-90FA-42D2C78535AFQ39390852-C9900F5C-D8FD-4B4E-8C88-80BDC98A2748Q39415199-EFB1F6E7-22CC-4D72-8793-3E5CD3568419Q39425138-C58B0E16-DA52-465D-B280-53DCD627EEDBQ41085174-6740F4C0-AD13-4B8D-9319-FE190F96B5DCQ41552575-0EF27842-C567-4FE2-A88A-5FA197529441Q41552614-C152F882-D099-4B48-80F8-9656BF5F1570Q41552639-67676740-1530-4BA5-B2E5-3FA26A84C848Q41659315-02EBED0E-3CAA-4343-917D-DC1BA89B1415Q41660847-C597CF6C-1DBA-4A5A-A861-8CB15FBC294BQ45068538-545ECD97-6BE9-4C30-8624-40ACF0B217F0Q46265960-1D49A296-8A9D-4595-8B44-5E6E5B9394CCQ46911300-60A6E10D-2C8F-4B48-8703-EE5A1F8117CAQ47103743-EEF07B8F-5EB5-4F9F-BE0E-DA63805DBDDBQ47106921-A2543185-911F-4BA9-B3DD-5B17C7B5E886Q47126078-668E72A1-6759-4EC2-8771-9073E729E8D1Q47137624-0A6596C3-37F4-416F-AF60-354F8A515BC4Q47139880-C030E030-E8B7-474E-A51E-F9C323C58191Q47162721-D9449D88-2901-4DB4-BB83-999AC9745182Q47169621-395458B7-7AAA-4753-B78E-D262BB843CD3Q47260956-E677E245-6BCF-41AC-936B-4151D5DCAF9BQ47283159-AFC64828-9CFF-496E-81E9-E259AB2B3030Q47608670-6567B913-D26C-46C2-801F-7E8C9EBCD238Q47673602-0EA15C9F-04B7-49D9-9CBF-7C5E40E0E2D4Q47843948-4ED09489-B154-4A89-AF5A-4ABE36556507Q48146766-B47F93F7-169D-4F83-BE34-921B07E44C4FQ48162218-BD3C05C7-6099-446B-A6F6-CAB8BA872E42Q48199906-6B3CFD75-2558-47DE-ABDB-A3E66558678FQ48251370-4B678259-F00C-4864-91C1-549EB5F2ABA2Q48507168-FB7CD7D1-C55A-4DA2-9BD1-A3482CB8B163Q48507592-0CD4E3CF-283C-4A4C-B5FF-A5275782CA0BQ49218448-247C29AF-785B-4CD6-87FF-660B9D6CC49AQ49221322-9279CC23-3B2E-4867-88CF-8DACF1582B7CQ49708541-6BA81A75-1F88-450B-B18B-D8EDAA50E55EQ49710389-DF1F52F8-51FC-45CD-A1CD-F07197C78CBDQ49887930-67B801A7-AF15-4821-88EB-BF5B883587A8Q49887950-A2392A46-DE8F-4860-B379-57F7714B4EF4
P2860
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
@en
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
@nl
type
label
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
@en
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
@nl
prefLabel
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
@en
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
@nl
P2860
P1476
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
@en
P2093
Tsukasa Shibue
P2860
P304
P356
10.1038/NRCLINONC.2017.44
P407
P577
2017-04-11T00:00:00Z